Oslo, December 8, 2017 Bionor was purchased by the founder of Bionor AS, Birger Sørensen and his team, on September 28, 2017 with financial closing as of today. With the assistance of Norse Securities, the new owners/management have successfully raised funds for the purchase and future operations. Birger Sørensen and his team will immediately start …
Oslo, November 24, 2017 Bionor is proud to announce that the company on November 24 entered into a strategic partnership with Smerud Medical Research International (SMRI). This partnership will focus on the clinical and regulatory development program towards a marketing approval and will also cover other development aspects such as financing and commercialization.
Bionor’s strategy is to develop the combination of its two proprietary therapeutic HIV vaccines Vacc-4x and Vacc-C5 and seek advice on and adapt its regulatory path so that a marketing approval for a functional cure for HIV can be achieved. As part of this strategy, Bionor will extend and complete the Vacc-C5 dose escalation studies …
